HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Initial results of treatment with the new antidepressant Upstene].

Abstract
On 52 cases treated with Upstene IV or per os, in double blind with clomipramine or in open study, we have obtained 47 good or excellent results. The remission can be spectacular and obtained very rapidly in 1 to 4 days. Upstene does not give any secondary effects. A remarquable specificity of Upstene has been observed in obsessionnal and phobic neuroses: 25 positive results on 27 cases. Upstene is very active on 5 HT reuptake, particularly in the limbic system; it reduces cutral 5 HIAA metabolism which would probably explain its beneficial effect on obsessional or phobic neuroses, in which 5 HIAA is increased in the brain. Furthermore, limbic lobectomy gives 84% of positive results.
AuthorsA Wauters
JournalActa psychiatrica Belgica (Acta Psychiatr Belg) 1983 Jan-Feb Vol. 83 Issue 1 Pg. 69-74 ISSN: 0300-8967 [Print] Belgium
Vernacular TitlePremiers résultats du traitement par le nouvel antidépresseur Upstène.
PMID6613613 (Publication Type: Comparative Study, English Abstract, Journal Article)
Chemical References
  • Antidepressive Agents
  • Piperidines
  • Clomipramine
  • indalpine
Topics
  • Antidepressive Agents (therapeutic use)
  • Clomipramine (therapeutic use)
  • Depressive Disorder (drug therapy, psychology)
  • Double-Blind Method
  • Humans
  • Obsessive-Compulsive Disorder (drug therapy)
  • Phobic Disorders (drug therapy)
  • Piperidines (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: